Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Hepion Pharmaceuticals, Inc.

HEPA · OTC · CIK 0001583771 · Healthcare · Biotechnology

INSIDER SIGNAL

82.0 / 100

6 buyers · 7 purchase transaction lines · $835.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeModerate
RoleModerate
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+35.0 / 35
Purchase size+16.9 / 25
Role+13.0 / 20
Recency+7.2 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Role scores low · most senior buyer: Interim CEO (CEO, chair and 10% owners score lowest)
  • ✓ Cluster breadth is broad · 4+ insiders
  • ✓ Recent activity · latest purchase 2026-09-29

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS6
PURCHASE CONCENTRATION60%Largest buyer: LoPriore Vincent S · $500.0K
CLUSTER BUYING · 15D5 insidersPeak activity: 2026-08-03–2026-08-03

Roles in the peak window: Chief Operating Officer, Director, Executive Chairman, Interim CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Stetz Gary S. IIDirector
●
Stetz Gary S.Interim CEO
●
Purcell Michael J.Director
●
Appajosyula SireeshChief Operating Officer
●
LoPriore Vincent SExecutive Chairman
●
Fisher DaninaDirector
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

82.0 / 100

Latest recorded score

↓ -1.8 ptsversus the previous recorded snapshot
  1. 84.4
  2. 84.3
  3. 84.0
  4. 83.8
  5. 82.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

12Purchases
0Sales
0Other Form 4 lines
10SEC filings · 365 days
BUYING7 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+60.0%
3M
+100.0%
6M
+166.7%
12M
+53.8%

Volatility & liquidity

Volatility
246.5%
Beta
—
Avg daily value
USD 4,898

Valuation

Market cap
USD 10.8M
P/E
—

Fundamentals

Profit margin
—
ROE
-310.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-10 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
14,862
Previous report
4,816
Avg daily volume
108,951
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29Fisher DaninaPurchase (P)Common Stock200,000USD 0.05USD 10,000SEC filing ↗
2026-08-03Stetz Gary S. IIPurchase (P)Common Stock500,000USD 0.05USD 25,000SEC filing ↗
2026-08-03Stetz Gary S.Purchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-08-03Purcell Michael J.Purchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-08-03LoPriore Vincent SPurchase (P)Common Stock10,000,000USD 0.05USD 500,000SEC filing ↗
2026-08-03Appajosyula SireeshPurchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-04-21Stetz Gary S.Purchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗
2026-04-21Purcell Michael J.Purchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗
2026-04-21LoPriore Vincent SPurchase (P)Common Stock, par value $0.0001 per share6,250,000USD 0.04USD 250,000SEC filing ↗
2026-04-21Appajosyula SireeshPurchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗
2023-11-27Wijngaard PeterPurchase (P)Common Stock2,500USD 3.05USD 7,625SEC filing ↗
2023-11-24Wijngaard PeterPurchase (P)Common Stock2,500USD 3.09USD 7,725SEC filing ↗
2023-09-19Wijngaard PeterPurchase (P)Common Stock1,000USD 5.64USD 5,640SEC filing ↗
2023-09-18Foster Robert TPurchase (P)Common Stock1,600USD 5.60USD 8,960SEC filing ↗
2023-09-15Wijngaard PeterPurchase (P)Common Stock2,000USD 5.60USD 11,201SEC filing ↗

Form 4 evidence

12 transaction lines in the latest 365-day window; 28 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29Fisher DaninaPurchase (P)Common Stock200,000USD 0.05USD 10,000SEC filing ↗
2026-08-03Stetz Gary S. IIPurchase (P)Common Stock500,000USD 0.05USD 25,000SEC filing ↗
2026-08-03Stetz Gary S.Purchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29Fisher DaninaPurchase (P)Common Stock200,000USD 0.05USD 10,000SEC filing ↗
2026-08-03Stetz Gary S. IIPurchase (P)Common Stock500,000USD 0.05USD 25,000SEC filing ↗
2026-08-03Stetz Gary S.Purchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-08-03Purcell Michael J.Purchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-08-03LoPriore Vincent SPurchase (P)Common Stock10,000,000USD 0.05USD 500,000SEC filing ↗
2026-08-03Appajosyula SireeshPurchase (P)Common Stock2,000,000USD 0.05USD 100,000SEC filing ↗
2026-04-21Stetz Gary S.Purchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗
2026-04-21Purcell Michael J.Purchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗
2026-04-21LoPriore Vincent SPurchase (P)Common Stock, par value $0.0001 per share6,250,000USD 0.04USD 250,000SEC filing ↗
2026-04-21Appajosyula SireeshPurchase (P)Common Stock, par value $0.0001 per share1,250,000USD 0.04USD 50,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerHEPA
CIK0001583771
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeOTC

Data coverage

Local Form 4 history28 transaction lines from 2020-11-25 to 2026-09-29
28 P purchase lines · 0 S sale lines · 0 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.